Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
- Conditions
- Healthy
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 16
- Registration Number
- NCT00409929
- Locations
- π¨π
Novartis Investigative Site, Bern, Switzerland
Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42
- Registration Number
- NCT00410228
- Locations
- π¨π
Novartis Investigative Site, Bern, Switzerland
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1930
- Registration Number
- NCT00409760
- Locations
- π©πͺ
Sites in Germany, Multiple Locations, Germany
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1259
- Registration Number
- NCT00409643
- Locations
- π©πͺ
Sites in Germany, Germany, Germany
πΊπΈNovartis Pharmaceuticals, East Hanover, New Jersey, United States
One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1293
- Registration Number
- NCT00409851
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Behavioral: Behavior Therapy
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 142
- Registration Number
- NCT00409708
- Locations
- πΊπΈ
Novartis Pharmaceuticals Investigational site, Houston, Texas, United States
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
- Conditions
- Post Acute Coronary SyndromeMyocardial Ischemia
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1101
- Registration Number
- NCT00409578
- Locations
- πΈπͺ
Investigative Site, Investigative Site, Sweden
Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00409500
- Locations
- π―π΅
Novartis Investigative Site, Tokyo, Japan
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
- Conditions
- Parkinson's Disease
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 301
- Registration Number
- NCT00407212
- Locations
- π«π·
Novartis Investigative Site, Paris, France
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 52
- Registration Number
- NCT00406016
- Locations
- π¨π
Novartis Investigative Site, Zuerich, Switzerland
π¨πNovartis Investigative site, Zurich, Switzerland